One approach to overcome this problem would be to separate drug–antibody complexes prior to or during the assay procedure ... antibodies and other TNF-α neutralizing factors such as soluble ...

It’s one of several tools doctors can utilize to improve diagnosis of patients, and in 2024, the company licensed its antibody to Roche to include in Roche’s diagnostic antibody-based testing ...

The company aims to supercharge antibody treatments using specially designed protein “cages” that multiply their effects, opening up new opportunities in drug development. The company was spun ...